Kura Oncology (KURA) Set to Announce Earnings on Thursday

Kura Oncology (NASDAQ:KURA) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.64) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same period in the previous year, the company posted ($0.53) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, analysts expect Kura Oncology to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $17.52 on Wednesday. The business has a 50-day simple moving average of $18.95 and a 200-day simple moving average of $20.02. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology has a one year low of $8.17 and a one year high of $24.17. The company has a market cap of $1.34 billion, a PE ratio of -7.86 and a beta of 0.86.

Analyst Ratings Changes

KURA has been the topic of a number of recent analyst reports. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. UBS Group began coverage on Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a report on Monday, October 14th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Finally, Wedbush restated an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.